Premium
Monoclonal antibody OKT17 recognizes most cases of T‐cell malignancy
Author(s) -
Matutes E.,
Parreira A.,
Foa R.,
Catovsky D.
Publication year - 1985
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1985.tb02879.x
Subject(s) - monoclonal antibody , antigen , antibody , t cell , microbiology and biotechnology , biology , phenotype , cell , monoclonal , immunology , genetics , gene , immune system
S ummary . Membrane phenotype analysis with monoclonal antibodies (McAb) has demonstrated great heterogeneity within the T‐cell malignancies. We describe here the reactivity with an anti‐T cell McAb, OKT17, in 80 leukaemia samples. Cells from all types of T‐cell leukaemia (48 cases), except from the small group of pre‐T‐ALL, strongly expressed the antigen identified by OKT17 whereas none of the 32 non‐T leukaemias were OKT17 positive. When the reactivity of OKT17 was compared with that of other pan‐T markers, OKT17 was positive in a larger number of T‐cell leukaemias: 87% of cases compared with 74% with E‐rosettes and 73% with the McAb 3A1. In the mature or post‐thymic proliferations OKT17 was positive in 96% of cases, compared with 77% with E‐rosettes and 61% with 3A1. The latter reagent, on the other hand, was better than OKT17 for detecting leukaemias with a thymic phenotype, 100% and 68% of positive cases respectively. The combined use of OKT17, 3A1 and terminal transferase permits a more precise classification of all the T‐cell leukaemias according to the main stages of T‐cell differentiation.